Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled,
parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS
patients with spasticity.
Eligible subjects will be removed from anti-spasticity mediations for at least one week and
then begin study drug treatment with daily doses increasing up to the target dose which will
then be maintained for at least 12 weeks. A down-titration will then occur over two weeks
with the final study visit occuring at 19 weeks from start of achieving the target dose or 22
weeks from the Study Visit 1.